Evolent Health (EVH)·Q4 2025 Earnings Summary

Evolent Health Posts $398M Goodwill Impairment, Stock Hits 52-Week Low

February 24, 2026 · by Fintool AI Agent

Evolent Health (NYSE: EVH) delivered a mixed Q4 2025 report that sent shares tumbling to a new 52-week low despite beating adjusted EPS estimates. The specialty care management company reported a $398 million goodwill impairment that drove a massive GAAP loss, while elevated medical costs pushed the medical expense ratio to concerning levels. Management maintained an optimistic outlook, guiding for ~30% revenue growth in FY 2026 as $900 million in new Performance Suite contracts ramp up.

Did Evolent Health Beat Earnings?

Bottom line: Beat on EPS and EBITDA, slight miss on revenue, but the optics were terrible.

The adjusted metrics tell one story—margin discipline and cost management. The GAAP results tell another—a $398M goodwill impairment reflecting the dramatic decline in the company's market value from $2.5B to under $300M over the past year.

How Did the Stock React?

EVH shares fell 6.7% to $2.56, hitting a new 52-week low and extending an extraordinary decline:

The chart above shows EVH's dramatic fall from grace. The company beat estimates in Q1-Q3 2024, but the Q3 2024 massive EPS miss ($0.04 vs $0.34 expected) marked the inflection point. Since then, the stock has been in freefall as medical cost headwinds and customer membership losses accumulated.

What Changed From Last Quarter?

The key deterioration centers on the Medical Expense Ratio (MER), which measures claims costs relative to Performance Suite revenue:

The MER excluding Evolent Care Partners at 94.8% is particularly concerning—it means nearly 95 cents of every Performance Suite dollar goes to medical claims, leaving minimal margin for operating costs and profit.

What Did Management Guide?

CEO Seth Blackley maintained an optimistic tone despite the challenging results, guiding for strong growth in 2026:

The disconnect is stark: Revenue is expected to grow ~30%, yet Adjusted EBITDA is guided down. Management attributes this to:

1. $900M in new Performance Suite revenue that carries initial reserving effects and ramp costs
2. Health plan Exchange membership losses impacting existing contracts
3. Operating cost reductions that will take time to materialize across 2026

Key Management Commentary

Seth Blackley, CEO, struck an optimistic tone despite the results:

"In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximately 30% for 2026 demonstrates the power and durability of Evolent's specialty model."

On near-term margin pressure:

"While the addition of $900 million in new Performance Suite revenue in 2026, as well as the impact of significant health plan customer membership decreases in their Exchange products, create an impact on Adjusted EBITDA in the first half of the year, we believe our year-end 2026 margins should quickly step-up as new contract reserving effects ease throughout the year."

Balance Sheet & Liquidity

The balance sheet deterioration reflects the goodwill impairment and increased leverage. Total debt increased by $257M YoY as the company drew on credit facilities. The company also repurchased $40M of stock during 2025.

Year-Over-Year Comparison

Despite the 27.5% revenue decline (largely from the Evolent Care Partners divestiture), Adjusted EBITDA margins more than doubled—reflecting improved operational efficiency on the remaining business.

Segment Breakdown

Key Risks to Watch

Management highlighted several risk factors in the filing:

1. Customer concentration - Significant revenue from largest partners
2. Performance-based contract risk - Increasing exposure to medical cost volatility
3. Exchange membership declines - Health plan partners losing ACA marketplace members
4. Elevated medical costs - Industry-wide trend impacting MER
5. Debt levels - Increased leverage with $971M in total debt
6. Integration risk - Ability to successfully ramp new Performance Suite contracts

Forward Catalysts

The Bottom Line

Evolent delivered operationally on adjusted metrics but faces severe investor skepticism reflected in the stock's 75% YoY decline. The investment case hinges entirely on execution: can management ramp $900M in new Performance Suite revenue while controlling medical costs and delivering on the EBITDA recovery promised for H2 2026? At a $297M market cap against $2.5B in guided revenue, the stock is pricing in significant execution risk or potential for further deterioration.